ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.

Meredith M Regan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.